×
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
NASDAQ:TXMD

TherapeuticsMD News Headlines

$2.15
-0.41 (-16.02%)
(As of 05/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.05
$2.40
50-Day Range
$2.15
$21.78
52-Week Range
$2.05
$69.50
Volume
1.52 million shs
Average Volume
478,332 shs
Market Capitalization
$18.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.09
Get TherapeuticsMD News Delivered to You Automatically

Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

TherapeuticsMD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TXMD
News Sentiment

0.64

0.55

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TXMD Articles
This Week

8

2

TXMD Articles
Average Week



TherapeuticsMD (NASDAQ:TXMD) News Headlines Today

SourceHeadline
marketwatch.com logoTherapeuticsMD Shares Drop 9% After Big Move Higher Friday - MarketWatch
marketwatch.com - May 23 at 2:44 PM
benzinga.com logoTherapeuticsMD Receives FDA Approval For Supplemental New Drug Application For ANNOVERA - Benzinga - Benzinga
benzinga.com - May 21 at 6:42 AM
marketwatch.com logoTherapeuticsMD Shares Rise 22% After FDA Approval of Supplemental NDA - MarketWatch
marketwatch.com - May 20 at 3:40 PM
MarketBeat logoFY2022 Earnings Estimate for TherapeuticsMD, Inc. (NASDAQ:TXMD) Issued By Cantor Fitzgerald
americanbankingnews.com - May 20 at 1:52 AM
benzinga.com logoTherapeuticsMD: Q1 Earnings Insights - Benzinga - Benzinga
benzinga.com - May 16 at 8:43 PM
investing.com logoTherapeuticsMD Misses Q1 EPS by $1.69 By Investing.com - Investing.com
investing.com - May 16 at 8:43 PM
businesswire.com logoTherapeuticsMD Announces First Quarter 2022 Financial Results - Business Wire
businesswire.com - May 16 at 8:43 PM
finance.yahoo.com logoTherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript
finance.yahoo.com - May 16 at 8:43 PM
seekingalpha.com logoTherapeutics MD Q1 2022 Earnings Preview (NASDAQ:TXMD) - Seeking Alpha
seekingalpha.com - May 15 at 6:24 PM
MarketBeat logoTherapeuticsMD (TXMD) Scheduled to Post Quarterly Earnings on Monday
americanbankingnews.com - May 14 at 1:54 AM
nasdaq.com logoHarpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
nasdaq.com - May 13 at 2:40 AM
businesswire.com logoTherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 - Business Wire
businesswire.com - May 12 at 4:59 AM
MarketBeat logoTherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Down 97.6% in April
americanbankingnews.com - May 12 at 2:50 AM
finance.yahoo.com logoSupporters of the NECEC Argue November Referendum Is Unconstitutional - Yahoo Finance
finance.yahoo.com - May 10 at 9:01 PM
benzinga.com logoTherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 - Benzinga - Benzinga
benzinga.com - May 10 at 9:01 PM
MarketBeat logoTherapeuticsMD (NASDAQ:TXMD) Sets New 1-Year Low at $4.11
americanbankingnews.com - May 10 at 4:22 AM
MarketBeat logoTherapeuticsMD (NASDAQ:TXMD) Rating Lowered to Neutral at Cantor Fitzgerald
americanbankingnews.com - May 8 at 4:00 AM
benzinga.com logoCantor Fitzgerald Downgrades TherapeuticsMD to Neutral, Lowers Price Target to $1 - Benzinga - Benzinga
benzinga.com - May 6 at 7:56 AM
MarketBeat logoTherapeuticsMD Stock Set to Reverse Split on Monday, May 9th (NASDAQ:TXMD)
americanbankingnews.com - May 1 at 1:16 AM
time.com logoWhy Your Insurance Doesn't Want to Cover Your Birth Control - TIME
time.com - April 25 at 7:17 AM
finance.yahoo.com logoThe Global Vaginal Ring Market is expected to grow by $ 519.39 mn during 2022-2026 progressing at a CAGR of 4.44% during the forecast period - Yahoo Finance
finance.yahoo.com - April 19 at 6:56 AM
businesswire.com logoTherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million - Business Wire
businesswire.com - April 15 at 1:52 AM
finance.yahoo.com logoTherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million - Yahoo Finance
finance.yahoo.com - April 14 at 8:52 PM
finance.yahoo.com logoTherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
finance.yahoo.com - April 14 at 8:52 PM
seekingalpha.com logoHaemonetics names new CFO - Seeking Alpha
seekingalpha.com - March 22 at 4:38 AM
finance.yahoo.com logoKamada Expands U.S. Leadership Team with Two Key Appointments - Yahoo Finance
finance.yahoo.com - March 14 at 9:16 AM
seekingalpha.com logoTherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business - Seeking Alpha
seekingalpha.com - March 14 at 9:16 AM
benzinga.com logoHC Wainwright & Co. Maintains Buy on TherapeuticsMD, Lowers Price Target to $2.5 - Benzinga - Benzinga
benzinga.com - March 11 at 3:01 PM
seekingalpha.com logoTherapeuticsMD price target lowered at H.C. Wainwright on supply constraints - Seeking Alpha
seekingalpha.com - March 11 at 10:00 AM
fool.com logoTherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript - The Motley Fool
fool.com - March 11 at 4:59 AM
nasdaq.com logoTherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates - Nasdaq
nasdaq.com - March 10 at 11:59 PM
businesswire.com logoTherapeuticsMD Announces Fourth Quarter 2021 Financial Results - Business Wire
businesswire.com - March 10 at 6:58 PM
benzinga.com logoTherapeuticsMD: Q4 Earnings Insights - Benzinga - Benzinga
benzinga.com - March 10 at 1:58 PM
finance.yahoo.com logoTherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
finance.yahoo.com - March 10 at 1:58 PM
finance.yahoo.com logoTherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript
finance.yahoo.com - March 10 at 1:58 PM
benzinga.com logoTherapeuticsMD Earnings Preview - Benzinga - Benzinga
benzinga.com - March 9 at 2:47 PM
benzinga.com logoMid-Afternoon Market Update: Crude Oil Rises Over 3%; Niu Technologies Shares Plunge - Benzinga - Benzinga
benzinga.com - March 9 at 12:02 AM
benzinga.com logoMid-Afternoon Market Update: Crude Oil Rises Over 3%; Niu Technologies Shares Plunge - Benzinga
benzinga.com - March 8 at 2:01 PM
finance.yahoo.com logoTherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal
finance.yahoo.com - March 8 at 9:00 AM
benzinga.com logoMid-Day Market Update: Nasdaq Drops 250 Points; Bed Bath & Beyond Shares Surge - Benzinga - Benzinga
benzinga.com - March 7 at 3:02 PM
benzinga.com logoTherapeuticsMD shares are trading higher after the company announced it would sell its vitaCare business to GoodRx for $150M. - Benzinga
benzinga.com - March 7 at 3:02 PM
streetinsider.com logoPre-Open Stock Movers 03/07: (BBBY) (TXMD) (OXY) Higher; (ALPN) (SQSP) (BLUE) Lower (more...) - StreetInsider.com
streetinsider.com - March 7 at 10:02 AM
finance.yahoo.com logoTherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx - Yahoo Finance
finance.yahoo.com - March 7 at 10:02 AM
marketwatch.com logoTherapeuticsMD Inc. stock falls Thursday, still outperforms market - MarketWatch
marketwatch.com - March 4 at 6:01 AM
finance.yahoo.com logoGynecology Drugs Global Market Report 2022 - Yahoo Finance
finance.yahoo.com - March 3 at 9:52 AM
finance.yahoo.com logoTherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022 - Yahoo Finance
finance.yahoo.com - March 1 at 9:59 PM
finance.yahoo.com logoTherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
finance.yahoo.com - March 1 at 9:59 PM
nasdaq.com logoRadius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
nasdaq.com - February 24 at 1:02 PM
benzinga.com logoKaren L. Ling joins Galderma's Advisory Committee - Benzinga - Benzinga
benzinga.com - February 18 at 2:32 AM
nasdaq.com logoInsiders may be rethinking their US$1.4m TherapeuticsMD, Inc. (NASDAQ:TXMD) investment now that the company has lost US$28m in value - Nasdaq
nasdaq.com - January 28 at 2:14 PM
Get TherapeuticsMD News Delivered to You Automatically

Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.